alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Phase 1 Recruiting 49 enrolled Celyad Oncology SA

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

Timeline

Start: 2018-11-28
Primary completion: 2021-11-28
Completion: 2036-02-17

Publications

Michaux A, Mauen S, Breman E, Dheur MS, Twyffels L, Saerens L, Jacques-Hespel C, Gauthy E, Agaugue S, Gilham DE, Sotiropoulou PA. Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy. J Immunother. 2022 Apr 1;45(3):150-161. doi: 10.1097/CJI.0000000000000413.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CYAD-101	Cell therapy	—	—
Background	Irinotecan	Small molecule	—	—
Background	Leucovorin	Small molecule	—	—
Background	Oxaliplatin	Small molecule	—	—
Background	fluorouracil	Small molecule	—	—

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Summary

Timeline

Publications

Drugs

Indications